IgA2<sup>+</sup> B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus.

The proportion of ITGB7 + IgA2 early PBs showed a trend toward reduction ( p = 0.058) ( Figures 4 D and 4E), while the proportion of ITGB1-expressing early PBs trended upward ( p = 0.073) ( Figure 4 D) after belimumab-rituximab combination therapy compared to after rituximab alone (where the proportion of ITGB7 + IgA2 early PBs increased).

also in 53,322 other papers